

Sina Noshad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11013790/publications.pdf>

Version: 2024-02-01

39
papers

1,332
citations

393982

19
h-index

360668

35
g-index

39
all docs

39
docs citations

39
times ranked

2640
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy. American Journal of the Medical Sciences, 2018, 355, 442-448.	0.4	12
2	Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 365-368.	1.8	20
3	Diabetes Care in Iran: Where We Stand and Where We Are Headed. Annals of Global Health, 2018, 81, 839.	0.8	62
4	National Prevalence of Self-Reported Coronary Heart Disease and Chronic Stable Angina Pectoris: Factor Analysis of the Underlying Cardiometabolic Risk Factors in the SuRFNCD-2011. Global Heart, 2018, 13, 73.	0.9	18
5	Prevalence of metabolic syndrome in Iran: A 2011 update. Journal of Diabetes, 2017, 9, 518-525.	0.8	33
6	Association of peripheral nesfatin-1 with early stage diabetic nephropathy. Pathophysiology, 2017, 24, 17-22.	1.0	7
7	Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific Reports, 2017, 7, 13461.	1.6	201
8	Inverse Association of Peripheral Orexin-A with Insulin Resistance in Type 2 Diabetes Mellitus: A Randomized Clinical Trial. Review of Diabetic Studies, 2017, 14, 301-310.	0.5	9
9	Zero and Five End-Digit Preference and Blood Pressure Quality of Care Revisited. Archives of Iranian Medicine, 2017, 20, 633-639.	0.2	2
10	Comment on Fischer et al. Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care 2016;39:1364â€“1370. Diabetes Care, 2016, 39, e206-e206.	4.3	7
11	Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. BMC Endocrine Disorders, 2016, 16, 35.	0.9	5
12	Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424â€“1430. Diabetes Care, 2016, 39, e189-e189.	4.3	2
13	Raised serum 25-hydroxyvitamin D levels in patients with active diabetic foot ulcers. British Journal of Nutrition, 2016, 115, 1938-1946.	1.2	35
14	Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis, 2016, 254, 42-51.	0.4	24
15	Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients. Annales D'Endocrinologie, 2016, 77, 586-592.	0.6	19
16	Channelopathy-related <i>SCN10A</i> gene variants predict cerebellar dysfunction in multiple sclerosis. Neurology, 2016, 86, 410-417.	1.5	23
17	Awareness, Treatment and Control of Pre-hypertension and Hypertension among Adults in Iran. Archives of Iranian Medicine, 2016, 19, 456-64.	0.2	31
18	Complementary and Alternative Medicine for the Treatment of Obesity: A Critical Review. International Journal of Endocrinology and Metabolism, 2015, 13, e19678.	0.3	67

#	ARTICLE	IF	CITATIONS
19	Association Of Peripheral 5-Hydroxyindole-3-Acetic Acid, A Serotonin Derivative, with Metabolic Syndrome and Low-Grade Inflammation. <i>Endocrine Practice</i> , 2015, 21, 711-718.	1.1	19
20	Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. <i>Endocrine Research</i> , 2015, 40, 14-19.	0.6	4
21	Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 412-419.	0.7	21
22	Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested case-control study. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 527-538.	1.5	28
23	Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2015, 9, 258-265.	1.8	18
24	Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance. <i>Diabetes and Metabolism Journal</i> , 2014, 38, 143.	1.8	25
25	Response: Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance (<i>Diabetes Metab J</i> 2014;38:143-9). <i>Diabetes and Metabolism Journal</i> , 2014, 38, 242.	1.8	4
26	Gender-specific changes in physical activity pattern in Iran: national surveillance of risk factors of non-communicable diseases (2007-2011). <i>International Journal of Public Health</i> , 2014, 59, 231-241.	1.0	52
27	Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, 319-327.	1.1	197
28	Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2014, 5, 327-332.	1.1	20
29	The Role of Metabolic Syndrome and Related Clinical Variables in Determining CEA Levels. <i>Advances in Clinical and Experimental Medicine</i> , 2014, 23, 907-912.	0.6	10
30	Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease. <i>Archives of Iranian Medicine</i> , 2014, 17, 596-601.	0.2	0
31	Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: A randomized clinical trial. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 501-507.	1.2	41
32	Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. <i>Regulatory Peptides</i> , 2013, 182, 1-6.	1.9	24
33	Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. <i>Clinical Nutrition</i> , 2013, 32, 179-185.	2.3	167
34	Accuracy of Anthropometric Parameters in Identification of High-risk Patients Predicted With Cardiovascular Risk Models. <i>American Journal of the Medical Sciences</i> , 2013, 346, 26-31.	0.4	10
35	Patterns of fruit and vegetable consumption among Iranian adults: a SuRFNCD-2007 study. <i>British Journal of Nutrition</i> , 2012, 108, 177-181.	1.2	49
36	Appropriate BMI cut-off values for identification of metabolic risk factors: Third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). <i>Annals of Human Biology</i> , 2012, 39, 484-489.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran. <i>Molecular Biology Reports</i> , 2012, 39, 6213-6218.	1.0	17
38	Contribution of Serum Leptin to Metabolic Syndrome in Obese and Nonobese Subjects. <i>Archives of Medical Research</i> , 2011, 42, 244-251.	1.5	28
39	Epidemiology and risk factors of the cardiometabolic syndrome in the Middle East. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 309-320.	0.6	13